Proactive Investors - Run By Investors For Investors

Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

Phase II clinical study results have revealed excellent safety and tolerability.
a representation of the human liver
Wider scope across a broad range of diseases

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

The company’s shares were last trading circa 54% higher intra-day, at $0.44.

A total of 133 non-alcoholic steatohepatitis (NASH) patients were enrolled into Immuron’s phase II NASH clinical study and were treated with either IMM-124E or placebo for 6 months.

Results demonstrate a statistically significant reduction of serum LPS levels

64.29% of patients treated with IMM-124E demonstrated a 15% or greater decrease in serum LPS levels compared with only 34.48% of patients showing a decrease for the placebo group, reaching statistical significance.

Importantly, no safety concerns or serious adverse events were associated with the study drug.

The 600mg and 1200mg doses were well tolerated and support the use of even higher doses and extended treatment periods in future clinical trials.

Wider scope across a broad range of diseases

Immuron’s study results offer evidence of a therapeutic mechanism of action and a clear direction for further NASH studies.

The growing literature implicating LPS in many diseases offers the potential for a much wider scope for LPS antagonism as a treatment modality.

With IMM-124E being the world’s first-in class oral LPS antagonist, the company has substantial opportunities across a broad range of diseases.

READ: Immuron achieves strong sales growth for travellers’ diarrhoea product

The company’s flag-ship product Travelan® achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
cannabis
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use